创新药赛道一骑绝尘 业内人士：普涨行情不可能持续

Core Viewpoint - The innovative drug sector is experiencing significant returns, with several ETFs showing over 100% returns year-to-date, indicating a strong performance trend in this investment area [1] Group 1: Performance of Innovative Drug ETFs - As of July 31, multiple innovative drug ETFs from Huatai-PB, Wanji Fund, and Huitianfu Fund have reported returns exceeding 100% this year [1] - Despite a recent pullback, the innovative drug theme ETFs remain one of the highest returning categories in the market [1] Group 2: Future Outlook - The innovative drug sector is expected to enter a "1-10" explosive growth phase, with more innovative drug products anticipated to launch domestically and representative new drugs emerging in overseas markets [1] - The investment approach in the innovative drug sector is shifting from "defensive allocation" to "offensive track," suggesting a more aggressive investment strategy [1] Group 3: Investment Considerations - The broad rally in the innovative drug sector is not expected to be sustainable; future excess returns will depend on investors' understanding and interpretation of information [1] - Only truly innovative drug companies with real capabilities are likely to attract investment interest moving forward [1]